An experimental subunit vaccine based on Bluetongue virus 4 VP2 protein fused to an antigen-presenting cells single chain antibody elicits cellular and humoral immune responses in cattle, guinea pigs and IFNAR(−/−) mice

Vaccine ◽  
2015 ◽  
Vol 33 (22) ◽  
pp. 2614-2619 ◽  
Author(s):  
D.M. Legisa ◽  
M.S. Perez Aguirreburualde ◽  
F.N. Gonzalez ◽  
A. Marin-Lopez ◽  
V. Ruiz ◽  
...  
Keyword(s):  
Immune Responses ◽  
Guinea Pigs ◽  
Bluetongue Virus ◽  
Subunit Vaccine ◽  
Single Chain ◽  
Single Chain Antibody ◽  
Vp2 Protein ◽  
Humoral Immune ◽  
Humoral Immune Responses ◽  
Antigen Presenting

scholarly journals Altered Humoral Immune Responses and IgG Subtypes in NOX2-Deficient Mice and Patients: A Key Role for NOX2 in Antigen-Presenting Cells

2018 ◽  
Vol 9 ◽  
Author(s):  
Julien Cachat ◽  
Christine Deffert ◽  
Marco Alessandrini ◽  
Pascale Roux-Lombard ◽  
Audrey Le Gouellec ◽  
...  
Keyword(s):  
Immune Responses ◽  
Antigen Presenting Cells ◽  
Humoral Immune ◽  
Humoral Immune Responses ◽  
Antigen Presenting ◽  
Deficient Mice

scholarly journals Recombinant Vesicular Stomatitis Virus Vectors Expressing Herpes Simplex Virus Type 2 gD Elicit Robust CD4+ Th1 Immune Responses and Are Protective in Mouse and Guinea Pig Models of Vaginal Challenge

2006 ◽  
Vol 80 (9) ◽  
pp. 4447-4457 ◽  
Author(s):  
Robert J. Natuk ◽  
David Cooper ◽  
Min Guo ◽  
Priscilla Calderon ◽  
Kevin J. Wright ◽  
...  
Keyword(s):  
Herpes Simplex ◽  
Immune Responses ◽  
Vesicular Stomatitis Virus ◽  
Guinea Pigs ◽  
Wild Type ◽  
Humoral Immune ◽  
Humoral Immune Responses ◽  
Vesicular Stomatitis ◽  
Simplex Virus

ABSTRACT Recombinant vesicular stomatitis virus (rVSV) vectors offer an attractive approach for the induction of robust cellular and humoral immune responses directed against human pathogen target antigens. We evaluated rVSV vectors expressing full-length glycoprotein D (gD) from herpes simplex virus type 2 (HSV-2) in mice and guinea pigs for immunogenicity and protective efficacy against genital challenge with wild-type HSV-2. Robust Th1-polarized anti-gD immune responses were demonstrated in the murine model as measured by induction of gD-specific cytotoxic T lymphocytes and increased gamma interferon expression. The isotype makeup of the serum anti-gD immunoglobulin G (IgG) response was consistent with the presence of a Th1-CD4+ anti-gD response, characterized by a high IgG2a/IgG1 IgG subclass ratio. Functional anti-HSV-2 neutralizing serum antibody responses were readily demonstrated in both guinea pigs and mice that had been immunized with rVSV-gD vaccines. Furthermore, guinea pigs and mice were prophylactically protected from genital challenge with high doses of wild-type HSV-2. In addition, guinea pigs were highly protected against the establishment of latent infection as evidenced by low or absent HSV-2 genome copies in dorsal root ganglia after virus challenge. In summary, rVSV-gD vectors were successfully used to elicit potent anti-gD Th1-like cellular and humoral immune responses that were protective against HSV-2 disease in guinea pigs and mice.

Nanoparticles and Vaccine Development

2020 ◽  
Vol 8 (1) ◽  
pp. 6-21 ◽  
Author(s):  
Mehdi kheirollahpour ◽  
Mohsen Mehrabi ◽  
Naser Mohammadpour Dounighi ◽  
Mohsen Mohammadi ◽  
Alireza Masoudi
Keyword(s):  
Immune Responses ◽  
Targeted Delivery ◽  
Vaccine Development ◽  
Inorganic Nanoparticles ◽  
Humoral Immune ◽  
Humoral Immune Responses ◽  
Vaccine Antigens ◽  
Specific Receptors ◽  
Delivery Vehicles ◽  
Antigen Presenting

In spite of the progress of conventional vaccines, improvements are required due to concerns about the low immunogenicity of the toxicity, instability, and the need for multiple administrations of the vaccines. To overcome the mentioned problems, nanotechnology has recently been incorporated into vaccine development. Nanotechnology increasingly plays an important role in vaccine development nanocarrier-based delivery systems that offer an opportunity to increase the cellular and humoral immune responses. The use of nanoparticles in vaccine formulations allows not only enhanced immunogenicity and stability of antigen, but also targeted delivery and slow release. Over the past decade, nanoscale size materials such as virus-like particles, liposomes, ISCOMs, polymeric, inorganic nanoparticles and emulsions have gained attention as potential delivery vehicles for vaccine antigens, which can both stabilize vaccine antigens and act as adjuvants. This advantage is attributable to the nanoscale particle size, which facilitates uptake by Antigen- Presenting Cells (APCs), then leading to efficient antigen recognition and presentation. Modifying the surfaces of nanoparticles with different targeting moieties permits the delivery of antigens to specific receptors on the cell surface, thereby stimulating selective and specific immune responses. This review provides an overview of recent advances in nanovaccinology.

Sign in / Sign up

Export Citation Format

Share Document